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Study Objectives: Our group and others have reported a high rate of vitamin D deficiency in obstructive sleep apnea (OSA), where vitamin D levels (25(OH)
D) correlate negatively with OSA severity and some of its associated metabolic alterations. Data regarding vitamin D supplementation in OSA are lacking. We 
wanted to evaluate the effect of vitamin D3 supplementation on OSA symptoms and metabolic parameters.
Methods: We conducted a pilot, double-blind, randomized, placebo-controlled trial of daily supplementation with 4,000 IU vitamin D3 (D3) or placebo 
(PL). We studied 19 Caucasian adults (14 male, mean age 55 y, mean body mass index [BMI] 30.4 kg/m2) with OSA. Fifteen patients were stable on 
continuous positive airways pressure (CPAP) therapy, whereas four were CPAP naïve. Assessments were completed at baseline and after 15 weeks of 
supplementation. Outcomes included sleepiness (Epworth Sleepiness Scale), quality of life (Sleep Apnea Quality of Life Inventory), fatigue (fatigue severity 
scale) and neuropsychological function (trail making test and Connor’s Continuous Performance Test II). In addition, we assessed biochemical indices of 
vitamin D status (25(OH)D, calcium), inflammation (high sensitivity C-reactive protein, and lipoprotein-associated phospholipase A2), lipids (total cholesterol 
[low-density and high-density lipoprotein]) and glycemic indices (fasting glucose, oral glucose tolerance test).
Results: There was no change in BMI, medication, or CPAP usage. Although there was no change in neuropsychological or quality of life indices, we 
observed a significant increase in 25(OH)D (p = 0.00001) and significant decreases in both low-density lipoprotein (p = 0.04) and lipoprotein-associated 
phospholipase A2 (p = 0.037) as well as trends toward decreased fasting glucose (p = 0.09) and increased high-density lipoprotein (p = 0.07) in the D3 group 
compared to PL.
Conclusions: Vitamin D3 supplementation increased vitamin D levels and decreased metabolic markers compared to placebo. Larger trials are required.
Keywords: inflammation; lipids; obstructive sleep apnea; vitamin D
Citation: Kerley CP, Hutchinson K, Bramham J, McGowan A, Faul J, Cormican L. Vitamin D Improves selected metabolic parameters but not 
neuropsychological or quality of life indices in OSA: a pilot study. J Clin Sleep Med. 2017;13(1):XXX–XXX.
INTRODUCTION
Obstructive sleep apnea (OSA) is strongly associated with obe-
sity, which is reported in up to 70% of cases. OSA incidence 
and/or severity is also related to ethnicity,1 winter season,2,3 
and lack of physical activity.4 Additionally, OSA has been as-
sociated with multiple metabolic disturbances including ex-
cess systemic inflammation, hyperglycemia, hyperlipidemia, 
cardiovascular disease, and increased bone loss.5
Vitamin D could, at least partially, mediate these relation-
ships. Indeed, recently there has been interest in the idea that 
vitamin D could be important for sleep disorders.6–8 A recent 
study suggested that the association between lower 25(OH)
D and OSA was largely confounded by larger BMI and neck 
circumference.9 In contrast, our group10 and others11–14 have 
reported a high rate of vitamin D deficiency in OSA, where 
vitamin D levels (25(OH)D) are lower in severe OSA10,11,13 and 
inversely correlate with some of its associated metabolic al-
terations, including abnormal glucose metabolism11,12 as well 
as nocturnal heart rate.10 Vitamin D receptors are located 
systemically and recent advances have demonstrated the po-
tential of vitamin D to influence a wide variety of organs.15 
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There is preliminary evidence that vitamin D supplementa-
tion may attenuate some metabolic disturbances through anti-
inflammatory, antihyperglycemic, and antihyperlipidemic 
roles, although these potential effects are inconsistent and 
controversial.
A recent comprehensive review regarding the link between 
vitamin D metabolism and sleep medicine concluded that con-
trolled studies are needed to further explore the relationship 
BRIEF SUMMARY
Current Knowledge/Study Rationale: Low vitamin D levels are 
common in subjects with obstructive sleep apnea and correlate 
with multiple cardiometabolic parameters. There is evidence the 
supplementing with vitamin D may improve several physiological, 
biochemical and subjective features of obstructive sleep apnea.
Study Impact: We present the first report of vitamin D 
supplementation in obstructive sleep apnea where 15 weeks of daily 
vitamin D supplementation at 4,000 IU/day decreased low-density 
lipoprotein cholesterol and systemic inflammation (lipoprotein-
associated phospholipase A2). Our pilot study is limited by small 
sample size and heterogeneous study sample, but may serve to 
increase knowledge and work in this area.
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between inadequate vitamin D and daytime neurocognitive 
impairment, OSA and associated morbidity, particularly car-
diovascular disease.16 Further, vitamin D supplementation may 
have roles regarding sleep quality,17 sleepiness,18,19 fatigue,20 
poor mood,21 and neuropsychological function.22 In this con-
text, it is noteworthy that a 2010 case study reported resolution 
of hypersomnia following vitamin D supplementation in a vi-
tamin D deficient, African American woman.18
To our knowledge, there are no reports regarding the ef-
fect of vitamin D supplementation in OSA. In this pilot study, 
we examined the effect of short-term vitamin D supplemen-
tation among urban adults with OSA, in terms of quality 
of life, neuropsychological function, and cardiovascular 
biomarkers.
METHODS
Subjects/Study Population
This pilot intervention study was conducted at Connolly Hos-
pital, Blanchardstown (Dublin 15, Ireland, latitude, 53°N) after 
institutional review board approval.
Inclusion criteria included previous OSA diagnosis by 
polysomnography (PSG), Caucasian race, and stable medical 
regimen including with or without CPAP for 6 mo or longer. 
Exclusion criteria included mixed sleep apnea, history of coro-
nary artery disease or diabetes or hypoglycemic agents and 
syndromes/therapy known to interfere with vitamin D metabo-
lism, including inflammatory bowel disease, as well as renal/
liver diseases and use of anticonvulsants, multivitamins, or vi-
tamin D. At baseline, trial information was provided and writ-
ten informed consent was obtained.
Study Design
This pilot study was designed as a parallel, randomized, dou-
ble-blind, placebo-controlled trial and involved two clinic vis-
its (Figure 1). Recruitment occurred between November 2013 
and January 2014, with follow-up 15 w later. All assessments 
were conducted at both baseline and follow-up in an identical 
manner at the same time of morning with the same researcher 
(CPK). Further, all assessments were conducted in the same 
windowless room with identical lighting and temperature con-
ditions. Following completion of day 1 presupplementation 
assessments, subjects were randomized to vitamin D3 (D3) or 
placebo (PL) groups using an online randomization program.
Assessments
PSG was conducted on all study participants as previously 
described.10 At each time point, subjects reported to our re-
search facility after an overnight fast, had blood drawn, and 
consumed 75 g of glucose. Next, a battery of self-report ques-
tionnaires was completed in the same order followed by neu-
ropsychological testing and a second blood sample was taken 
2 h after glucose ingestion (Figure 1). For those established 
on CPAP, compliance data were downloaded at baseline and 
endpoint. For those not established on CPAP, therapy was not 
initiated during this study.
The battery of self-report questionnaires included validated 
questionnaires regarding sleep quality sleepiness (Epworth 
Sleepiness Scale), quality of life (Sleep Apnea Quality of Life 
Inventory), fatigue (Fatigue Severity Scale), and mood (Beck 
Depression Inventory).
The neuropsychological testing included trail-making forms 
A and B and two subscales of the Repeatable Battery for the 
Assessment of Neuropsychological Status (R-BANS) (seman-
tic fluency and coding). Subjects also completed the computer-
ized Conner’s Continuous Performance test. Additionally, all 
participants completed the Wechsler test of adult reading at 
baseline only.
Biochemistry
Venous blood was analyzed locally for full blood count, glu-
cose, hemoglobin A1c, and lipids (total cholesterol, low-density 
lipoprotein [LDL], high-density lipoprotein [HDL], triglycer-
ides). Additional blood was centrifuged with isolated serum al-
iquoted and frozen to −80°C until required for further analysis.
Circulating levels of total 25-hydroxyvitamin D (25(OH)D) 
are considered the most reliable measure of overall vitamin D 
status because they reflect vitamin D2 + D3 contributions from 
all sources (i.e., diet, supplements, and sun exposure. 25(OH)
Figure 1—Trial design.
*Assessments included: fasting blood drawn, oral glucose tolerance test, 
Epworth Sleepiness Scale, Fatigue Severity Scale, Beck Depression 
Inventory and neuropsychological testing (trail making forms A and 
B, three subscales of Repeatable Battery for the Assessment of 
Neuropsychological Status and Conner’s Continuous Performance test. 
PL = placebo; D3 = vitamin D3
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D was measured using the Architect 25(OH)D chemilumines-
cent microparticle immunoassay (CMIA) with interassay coef-
ficient of variation of 3.5% and functional sensitivity less than 
20 nmol/L 25(OH)D, parathyroid hormone, insulin, high sensi-
tivity C-reactive protein, and lipoprotein-associated phospholi-
pase A2 (Lp-PLA2) were analyzed on Abbott Architect ci8200 
instrument (Abbott Laboratories, Abbott Park, IL, USA). The 
interassay coefficient of variation for these assays ranged be-
tween 1% and 5.6%. Lp-PLA2 activity was assessed using an 
enzyme-linked immunoassay (PLAC test, diaDexus, Inc., San 
Franciso, CA, USA). The range of detection is 10 – 400 nmol/
min/mL, with a clinical sensitivity less than 10 nmol/min/mL. 
Low Lp-PLA2 activity is indicated with values of 151 nmol/
min/mL or less, with medium values falling between 152–194 
nmol/min/mL and high values indicated by a result of 195 
nmol/min/mL or higher.
Supplements
At baseline, each subject was provided with a consecutively 
numbered bottle containing 120 softgel capsules of vitamin 
D3 (cholecalciferol) or identical placebo in a double-blind, ran-
domized fashion. A physician not involved in data gathering 
(JF) generated the allocation sequence, while a dietitian and 
nutrition researcher enrolled subjects (CPK). Subjects were in-
structed to ingest one softgel daily with food. The vitamin D 
dose was 4,000 IU daily, which corresponds to the tolerable 
upper intake limit in Europe.
Diet, supplement use, and particularly exposure to ultravio-
let B radiation contribute to vitamin D status. Therefore, we 
conducted this trial at high latitude during winter season when 
skin vitamin D synthesis is minimal. Further, we advised re-
cruits not to change dietary/supplemental behaviors during the 
trial. We assessed behavior relating to vitamin D status with 
the VIDSun questionnaire at baseline and endpoint, which 
contains questions relating to BMI, skin type, sun exposure, 
and supplement use.23 Supplement compliance was assessed 
with a diary and by counting the remaining softgels at the fol-
low-up visit.
Statistical Analysis
For this pilot study we did not conduct a sample size calcu-
lation. To our knowledge, this pilot study represents the only 
vitamin D supplementation trial in OSA and therefore we 
recruited a convenience sample to preliminary assess the ef-
fect, if any, of vitamin D3 supplementation in OSA. We used 
two-tailed, unpaired t-tests to compare baseline demograph-
ics between the two groups. We used two-tailed, paired t-tests 
to compare changes within groups and two-tailed, unpaired 
t-tests to compare changes between groups. All analyses were 
performed using a software package (SPSS, version 18; SPSS, 
Inc., Chicago, IL). Results were expressed as mean ± standard 
deviation. We defined statistical significance as p < 0.05.
RESULTS
We screened 97 adults attending sleep clinics of Connolly Hos-
pital. Of these 97, 40 were eligible and 26 provided consent. 
These 26 subjects were recruited and completed baseline as-
sessments. Of the 26, there were 7 dropouts for miscellaneous 
reasons (Figure 1). Baseline demographics for the 19 subjects 
who completed the study are presented in Table 1. The mean 
pretreatment 25(OH)D level for all patients was 37.2 nmol/L 
(range, 14.5 to 86.5 nmol/L) and there was no significant differ-
ence in baseline 25(OH)D levels between the PL and D3 groups. 
Further, there were no significant differences regarding age, 
BMI, sleepiness (Epworth Sleepiness Scale score), education 
level, or reading score between the D3 and PL group; however, 
there were more males in the PL group and more CPAP users 
in the D3 group.
Throughout the study, there was no change in medication 
or CPAP compliance in either group. In addition, there was no 
change in dietary habit or use of medication, alcohol, tobacco, 
or caffeine. Compliance with the supplements was high in both 
groups (93%) and there were no adverse effects.
Results before and after supplementation and comparisons 
between groups are displayed in Table 2 (biochemical indi-
ces), Table 3 (neuropsychological indices), and Table 4 (self-
reported questionnaire scores).
There was a significant increase in 25(OH)D, which was ac-
companied by a significant decrease in LDL and Lp-PLA2 in 
the vitamin D3 group compared to placebo. Additionally, there 
was a trend toward decreased fasting glucose and increased 
HDL in the D3 group (Table 2).
We did not detect any differences in neuropsychological in-
dices (Table 3) or quality of life scores (Table 4), except sig-
nificantly improved fatigue in the vitamin D group.
DISCUSSION
To our knowledge, this is the first report of vitamin D supple-
mentation in OSA. We investigated the effect of vitamin D3 
supplementation (4,000 IU/day) for 15 w compared to placebo 
among a small sample (n = 19) of urban, Caucasian adults with 
definite OSA as diagnosed by PSG. Consistent with previous 
studies9–14 we observed a high rate of vitamin D deficiency 
(89%) in our small OSA cohort. In addition to significantly 
increased 25(OH)D in the vitamin D supplementation group 
(n = 10), there were significant reductions in both LDL and 
Lp-PLA2 compared to placebo. Additionally, there was a trend 
toward decreased fasting glucose and increased HDL in the 
D3 group.
Interest in the potential role of vitamin D in sleep disorders 
has grown recently.6–8 We and others have observed wide-
spread vitamin D OSA.9–14 Interestingly, 25(OH)D levels have 
been shown to be inversely correlated with OSA severity10,11,13 
and with metabolic alterations associated with OSA, including 
abnormal glucose metabolism11,12 and nocturnal heart rate.10
A 2014 meta-analysis concluded that “Patients with OSA 
appear to have increased dyslipidemia (high total cholesterol, 
LDL, TG, and low HDL).” 24 Further, a large 2015 cross-sec-
tional study demonstrated an independent association between 
OSA and elevated LDL.25 The association between OSA and 
dyslipidemia may mediate some of the excess cardiovascular 
morbidity and mortality risk associated with OSA. Further, a 
4Journal of Clinical Sleep Medicine, Vol. 13, No. 1, 2017
CP Kerley, K Hutchinson, J Bramham, et al. Vitamin D Improves Metabolic Indices in OSA.
2014 mendelian randomization study concluded that interven-
tions that increased HDL may have an effect on coronary ar-
tery disease, but that interventions that decrease LDL have a 
stronger effect on coronary artery disease.26 CPAP represents 
the current gold standard treatment option for OSA and results 
in numerous biochemical and physiological benefits. How-
ever, the effect of CPAP on lipidemia is controversial. Two 
2014 meta-analyses provided conflicting evidence. One meta-
analysis concluded that “treatment for OSA seems to improve 
dyslipidemia (decrease in total cholesterol and LDL, and in-
crease in HDL).” 27 However, a second meta-analysis concluded 
that “CPAP did not alter TG, LDL, or HDL levels, suggesting 
that CPAP may have no clinically important effect on lipid me-
tabolism.” 28 Therefore, non-CPAP approaches to lipid lower-
ing in OSA are warranted. Although the association between 
vitamin D and cholesterol profiles is controversial, previous 
reports have demonstrated significantly negative correlations 
between serum LDL cholesterol and 25(OH)D.29–31 We provide 
evidence that vitamin D3 supplementation can modestly but 
significantly decrease serum LDL while maintaining serum 
HDL concentration in OSA over a 15 w period with no change 
in lifestyle or dietary intake. There was only a single subject 
on lipid-lowering therapy (Atorvastatin) in this pilot study. 
Interestingly, vitamin D supplementation decreased both to-
tal and LDL cholesterol in this subject (−0.3 and −0.44 mmol, 
respectively) despite concurrent lipid-lowering therapy, which 
can be expected to dilute any benefit.
Lp-PLA2 is a biomarker that may be viewed as a potential 
link between the pathogenic effects of oxidized LDL choles-
terol and plaque vulnerability. Although there is a lack of data 
regarding Lp-PLA2 and OSA, a recent cross-sectional study 
of 50 male Turkish subjects with newly diagnosed OSA dem-
onstrated a moderate linear relationship between arousal index 
and Lp-PLA2 levels.32 Because the arousal index is an impor-
tant index of sleep fragmentation and the restorative quality of 
sleep, this association may contribute to the increased cardio-
vascular risk association with frequent arousal in OSA. Fur-
ther, several epidemiology studies have shown an association 
between Lp-PLA2 and both cardiovascular and cerebrovascu-
lar events. We are not aware of any reports linking vitamin 
D and Lp-PLA2. The relationship between vitamin D and in-
flammation has been controversial. However, in vitro evidence 
suggests that vitamin D has potent anti-inflammatory proper-
ties.33,34 Further, there are reports of decreased production of 
several proinflammatory markers including tumor necrosis 
factor-α, interferon γ, and interleukins 2,12,17, and 2,1 but in-
creased production of anti-inflammatory interleukin-10 has 
been reported with vitamin D supplementation in humans.34 
Here, we observed a significant 19-point decrease in Lp-PLA2 
after vitamin D3 supplementation compared to placebo.
Table 1—Baseline demographics.
Placebo Vitamin D p*
n 9 10 –
Age, y, mean ± SD (range) 52 ± 13 (32 to 68) 56 ± 10 (42 to 71) 0.41
Males, n (%) 8 (89) 6 (60) –
AHI, mean ± SD (range) 37.3 ± 26.7 (8 to 86) 25.6 ± 22.1 (6 to 79) 0.31
CPAP users, n (%) 5 (55.6) 9 (90) –
Smoking status
Current, n 0 2 –
Ex-smoker, n 3 3 –
LLNS, n 6 5 –
BMI, kg/m2, mean ± SD (range) 32 ± 8 (23 to 49) 30 ± 4 (25 to 36) 0.49
Healthy range, n 2 1 –
Overweight, n 1 4 –
Obese, n 6 5 –
ESS (0 to 24), mean ± SD (range) 10 ± 6 (1 to 19) 11 ± 5 (3 to 19) 0.76
Years of education, mean ± SD (range) 13 ± 3 (8 to 18) 12 ± 4 (7 to 17) 0.54
WTAR Reading score (0 to 50), mean ± SD (range) 27 ± 12 (13 to 47) 31 ± 11 (12 to 45) 0.50
Fitzpatrick skin type †
1, n 1 0
2, n 1 4
3, n 6 6
4, n 1 0
25(OH)D (nmol/L), mean ± SD (range) 41.4 ± 22 (18.9 to 86.5) 33.4 ± 11.6 (14.5 to 47) 0.33
VDD at baseline, n (%) 7 (78) 10 (100) –
*p values derived from two-tailed, unpaired t-tests. † Fitzpatrick skin type derived from VIDSun questionnaire. AHI = apnea-hypopnea index; BMI = body 
mass index; ESS = Epworth Sleepiness Scale; LLNN = lifelong non-smoker; SD = standard deviation; VDD = vitamin D deficient (defined as 5 < 0 nmol/L); 
WTAR = Wechsler test of adult reading.
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Patients with OSA demonstrate cognitive dysfunction both 
subjectively and objectively.35 A recent comprehensive review 
concluded that controlled studies are needed to further explore 
the relation between inadequate vitamin D and daytime neu-
rocognitive impairment in OSA.7 There is much interest in the 
potential of vitamin D regarding cognition, with a recent meta-
analysis demonstrating that low 25(OH)D predicts executive 
dysfunctions, especially on mental shifting, information up-
dating, and processing speed.35 It is has been suggested that 
hypoxemia contributes more to cognitive dysfunction in OSA 
Table 2—Changes in biochemical indices.
Placebo Vitamin D p*
Baseline Endpoint Change Baseline Endpoint Change
25(OH)D (nmol/L) 41.4 ± 22
(18.9 to 86.5)
43.0 ± 21.4
(20.2 to 83.9)
1.6 33.4 ± 11.6
(14.5 to 47)
100.8 ± 39.9
(48.9 to 161.7)
67.4 0.00001
Fasting glucose 5.4 ± 1.1
(4.3 to 7.3)
5.9 ± 1.9
(4.6 to 10.8)
0.5 6.7 ± 2.6
(3.9 to 12.2)
6.3 ± 2.3
(3.7 to 11.8)
−0.4 0.09
2 h blood glucose 7.8 ± 3.3
(4.8 to 13.2)
7.3 ± 2.7
(4.8 to 12.4)
−0.5 9.6 ± 4.1
(5.0 to 16.4)
7.1 ± 2.8
(4.5 to 12.2)
−2.5 0.23
Glucose excursion 1.5 ± 3.6
(−6.0 to 6.3)
0.6 ± 4.7
(−10.8 to 5.7)
−0.9 1.9 ± 5.6
(−12.2 to 6.8)
0.1 ± 3.2
(−8.0 to 4.0)
−1.83 0.30
HbA1c 40.3 ± 8.7
(31.0 to 57.0)
38.4 ± 8.9
(30.0 to 51.0)
−1.9 51.7 ± 20.5
(35.0 to 90.0)
46.4 ± 17.0
(32.0 to 82.0)
−5.3 0.35
Insulin 19.3 ± 20.9
(6.6 to 69.0)
13.0 ± 10.4
(3.6 to 31.8)
−6.3 10.7 ± 3.9
(3.8 to 18.5)
11.6 ± 4.4
(3.6 to 16.9)
1.1 0.10
Total cholesterol 4.4 ± 1.1
(3.1 to 6.3)
4.2 ± 0.9
(3.3 to 5.9)
−0.2 4.6 ± 1.2
(2.8 to 6.2)
4.3 ± 0.9
(2.9 to 5.9)
−0.3 0.38
LDL 2.4 ± 0.8
(1.4 to 3.9)
2.5 ± 0.7
(1.7 to 3.9)
0.1 2.6 ± 0.9
(1.2 to 3.7)
2.3 ± 0.7
(1.6 to 3.8)
−0.3 0.04
HDL 1.2 ± 0.2
(0.9 to 1.7)
1.1 ± 0.1
(0.9 to 1.3)
−0.1 1.1 ± 0.3
(0.8 to 1.6)
1.1 ± 0.3
(0.7 to 1.5)
0.0 0.07
CRP 2.7 ± 2.7
(0.3 to 8.4)
2.5 ± 2.2
(0.1 to 7.0)
−0.2 4.7 ± 5.9
(0.1 to 18.5)
3.8 ± 3.8
(0.6 to 11.6)
−0.9 0.20
Lp-PLA2 173.0 ± 33.6
(100.0 to 207.0)
172.0 ± 34.7
(119.0 to 207.0)
−1.0 185.0 ± 42.0
(114.0 to 253.0)
166.0 ± 32.5
(111.0 to 202.0)
−19.0 0.037
Data are presented as mean ± standard deviation (range). *p values derived from one-tailed, unpaired t-tests comparing the change after placebo to change 
after vitamin D3. 25(OH)D = 25-hydroxyvitamin D; CRP = C-reactive protein; HbA1c = glycated haemoglobin; HDL = high-density lipoprotein; LDL = low-
density lipoprotein; Lp-PLA2 = lipoprotein-associated phospholipase A2; PTH = parathyroid hormone; TAG = triglycerides.
Table 3—Changes in neuropsychological indices.
Placebo Vitamin D p*
Baseline Endpoint Change Baseline Endpoint Change
Semantic fluency 17 ± 3
(12 to 22)
17 ± 34
(11 to 22)
0 18 ± 7
(11 to 34)
18 ± 4
(13 to 24)
0 0.26
Coding 35 ± 16
(5 to 65)
41 ± 13
(24 to 68)
6 36 ± 12
(24 to 53)
40 ± 13
(24 to 55)
4 0.10
Trail making A (sec) 35 ± 16
(22 to 72)
35 ± 18
(16 to 60)
0 33 ± 11
(16 to 54)
35 ± 13
(17 to 58)
2 0.40
Trail making B (sec) 89 ± 53
(33 to 209)
101 ± 52
(22 to 184)
11 97 ± 42
(32 to 175)
85 ± 36
(34 to 150)
−12 0.18
CPT II Omission T-score 71 ± 53
(42 to 209)
71. ± 45
(42 to 181)
0 74 ± 35
(40 to 143)
67 ± 22
(40 to 113)
−7 0.34
CPT II Omission percentile 61 ± 32
(22 to 99)
65 ± 34
(22 to 99)
4 72 ± 30
(18 to 99)
77 ± 28
(18 to 99)
−5 0.85
CPT II Commission T-score 53 ± 13
(38 to 76)
48 ± 10
(33 to 59)
−5 72 ± 7
(42 to 60)
49 ± 8
(39 to 62)
−3 0.43
CPT II Commission percentile 58 ± 35
(13 to 99)
49 ± 32
(5 to 83)
−9 57 ± 24
(223 to 84)
49 ± 27
(15 to 89)
−8 0.88
Data are presented as mean ± standard deviation (range). *p values derived from one-tailed, unpaired t-tests comparing the change after placebo to change 
after vitamin D3. CPT II = Conner’s Continuous Performance Test.
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than frequent arousals or daytime sleepiness.36 However, this 
suggestion is controversial. Considering that 90% of the vita-
min D supplementation group were CPAP users, any potential 
benefit of vitamin D supplementation in OSA could have been 
diluted. Therefore, although we performed very detailed neu-
ropsychological assessments and observed no cognitive benefit 
here, our small sample and the use of CPAP mean that this pilot 
study cannot rule out a potential benefit of vitamin D supple-
mentation in OSA.
Our pilot study has several strengths. We utilized the gold 
standard study design and assessed objective, subjective, and 
biochemical markers of OSA. We studied a well-characterized 
group of urban, Caucasian adults with definite OSA. The pla-
cebo and vitamin D groups were well matched at baseline with 
no significant differences in demographics. In the current study, 
all patients were Caucasian and resided in Dublin, Ireland. All 
of the 25(OH)D assays were conducted using the same batch 
of commercial assays and were performed concomitantly by 
the same biochemist in the same laboratory, thereby reducing 
biochemical variability. Vitamin D trials can be influenced by 
a number of factors, including fluctuations in sun exposure and 
hence 25(OH)D levels, variable quality of vitamin D assays, 
compliance with the intervention, and provision of inadequate 
vitamin D supplementation doses. To overcome these factors, 
we conducted this trial over the winter season at high latitude 
(53°N) when vitamin D photosynthesis is minimal. Although 
we purposely did not restrict nonprotocol dietary or supple-
mental vitamin D intake, we did ask that such behaviors were 
not altered during the trial. Identical vitamin D behaviors were 
evident in both groups throughout the trial as confirmed with 
VIDSun scores. Compliance, as assessed by diary data and 
capsule counts, was high (93%). We utilized a moderate-high 
dose of vitamin D3 (4,000 IU/day). In unison with our trial de-
sign and high compliance with the supplements, serum 25(OH)
D increased significantly in the vitamin D3 group, but did not 
change in the placebo group.
Our pilot study also has several important limitations. Al-
though there was no difference in 25(OH)D levels at base-
line, the mean 25(OH)D was higher in the placebo group. 
Twenty-two percent of subjects were vitamin D sufficient at 
baseline, which is of note because supplementation appears 
most beneficial to those with vitamin D deficiency. Further, 
as expected all recruits in the intervention arm had increases 
in 25(OH)D but three of the placebo group (33%) also experi-
enced increases in 25(OH)D (+10 to +22 nmol/L). Although 
we recruited an exclusively Caucasian sample, the sample was 
very small (n = 19) and heterogeneous in terms of CPAP us-
age. However, we ensured that CPAP was neither commenced 
nor discontinued throughout the trial. Further, we downloaded 
CPAP compliance data at baseline and endpoint, observing the 
CPAP usage did not change and ensuring that CPAP was care-
fully controlled during the study. An additional limitation is 
the lack of a power calculation and primary endpoint. However, 
the value of this pilot is to act as a hypothesis-generating basis 
for future work. It is possible that the statistical significance of 
our observations would be increased with a large sample size 
and a more homogeneous population.
CONCLUSIONS
In conjunction with a significant increase in 25(OH)D levels, 
this pilot study suggests that vitamin D supplementation has 
the potential to improve relevant biomarkers of cardiometa-
bolic health in OSA. It can be hypothesized that this effect 
may translate into clinical benefit over the long term due to 
decreased morbidity and mortality. Vitamin D replenish-
ment warrants further investigation as an adjunct therapeutic 
strategy in OSA.
ABBRE V I ATIONS
25(OH)D, 25-hydroxyvitamin D
AHI, apnea-hypopnea index
BDI, Beck depression inventory
BMI, body mass index
CAD, coronary artery disease
Table 4—Changes in self-reported questionnaire score.
Placebo Vitamin D p*
Baseline Endpoint Mean Change Baseline Endpoint Mean Change
ESS (0 to 24) 10 ± 6
(1 to 19)
7 ± 5
(0 to 16)
−3 11 ± 5
(3 to 19)
6 ± 2
(3 to 11)
−5 0.90
FSS (0 to 63) 46 ± 9
(29 to 58)
34 ± 8
(0 to 52)
−10 53 ± 7
(39 to 62)
38 ± 16
(0 to 57)
−14 0.31
SAQLI total score (0 to 7) 0.5 ± 0.2
(0.3 to 0.7)
0.5 ± 0.2
(0.2 to 0.7)
0 1.5 ± 0.3
(1.1 to 2)
1.9 ± 0.4
(1.3 to 2.4)
0.4 0.08
VIDSun score (0 to 7) 2 ± 1
(1 to 4)
2 ± 1
(1 to 4)
0 3 ± 1
(2 to 6)
2 ± 1
(1 to 4)
−1 0.002
BDI (0 to 63) 16 ± 10
(1 to 37)
12 ± 9.8
(0 to 28)
−4 14 ± 7
(2 to 23)
12 ± 9
(0 to 27)
−2 0.46
Data are presented as mean ± standard deviation (range). *p values derived from two-tailed, unpaired t-tests comparing the change after placebo to change 
after vitamin D3. BDI = Beck Depression Inventory; ESS = Epworth Sleepiness Scale; FSS = Fatigue Severity Scale; SAQLI = sleep apnea quality of life 
inventory; VIDSun = vitamin D + Sun questionnaire.
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CPT II, Conner’s Continuous Performance Test
CRP, C-reactive protein
ESS, Epworth Sleepiness Scale
HbA1c, glycated haemoglobin
HDL, high density lipoprotein
LDL, low density lipoprotein
LLNS, lifelong non-smoker
LP-PLA2, lipoprotein-associated phospholipase A2
OSA, obstructive sleep apnoea
PSG, polysomnography
PTH, parathyroid hormone
SAQLI, sleep apnea quality of life inventory
TAG, triacylglycerol
VDD, vitamin D deficiency
VIDSun, vitamin D + Sun questionnaire
WTAR, Wechsler test of adult reading
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